PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 521
- Registration Number
- NCT01942135
- Locations
- 🇺🇸
Holy Cross Hospital/Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States
🇺🇸Sylvester Comprehensive Cancer Center Deerfield Beach, Deerfield Beach, Florida, United States
🇺🇸Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT01939548
- Locations
- 🇺🇸
Comprehensive Clinical Development, Jamaica, New York, United States
🇺🇸Manhattan Psychiatric Center, Ward's Island, New York, United States
🇺🇸Comprehensive Clinical Development, Inc., Atlanta, Georgia, United States
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612Biological: Prevenar 13™
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 803
- Registration Number
- NCT01939158
- Locations
- 🇦🇺
Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺Vaccine and Immunization Research Group, Melbourne, Victoria, Australia
🇨🇿Krajska zdravotni, a.s., Nemocnice Decin, Decin, Czechia
Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Treatment of the Common Cold and Flu in Latin America
- Conditions
- Common Cold
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01938144
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Carcinoma
- Interventions
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT01937715
- Locations
- 🇺🇸
Drug Management Only: UCLA West Medical Pharmacy, Attn Steven L. Wong, Pharm .D., Los Angeles, California, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
🇺🇸Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
Drug Use Investigation for Toviaz
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2521
- Registration Number
- NCT01936870
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 311
- Registration Number
- NCT01934140
- Locations
- 🇵🇭
Philippine General Hospital, Manila, Philippines
🇵🇭Research Institute for Tropical Medicine, Muntinlupa City, Metro Manila, Philippines
Drug-Drug Interaction Study With PF-05089771
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2014-01-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT01934569
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT01934738
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT01934452
- Locations
- 🇫🇷
CHRU HOTEL DIEU - Service Urologie, Angers Cedex, France
🇫🇷CHU Strasbourg, Strasbourg, Cedex, France
🇫🇷C.H.U Morvan, Brest, France